Literature DB >> 14649217

Insulin glulisine. Aventis Pharma.

Daniela Barlocco1.   

Abstract

Aventis Pharma (formerly Hoechst Marion Roussel) is developing insulin glulisine, a fast-acting insulin analog, for the potential treatment of hyperglycemia in both type 1 and 2 diabetes. Aventis has submitted an NDA and an MAA to the FDA and the EMEA, respectively.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14649217

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  8 in total

Review 1.  Special considerations with insulin therapy in older adults with diabetes mellitus.

Authors:  Arshag D Mooradian
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.

Authors:  Daniel F Berenson; Allison R Weiss; Zhu-Li Wan; Michael A Weiss
Journal:  Ann N Y Acad Sci       Date:  2012-03-13       Impact factor: 5.691

3.  An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein.

Authors:  Michael D Glidden; Khadijah Aldabbagh; Nelson B Phillips; Kelley Carr; Yen-Shan Chen; Jonathan Whittaker; Manijeh Phillips; Nalinda P Wickramasinghe; Nischay Rege; Mamuni Swain; Yi Peng; Yanwu Yang; Michael C Lawrence; Vivien C Yee; Faramarz Ismail-Beigi; Michael A Weiss
Journal:  J Biol Chem       Date:  2017-11-07       Impact factor: 5.157

Review 4.  A critical appraisal of the role of insulin analogues in the management of diabetes mellitus.

Authors:  Ralph Oiknine; Marla Bernbaum; Arshag D Mooradian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Insulin therapy.

Authors:  Monika Lechleitner; Friedrich Hoppichler
Journal:  Wien Med Wochenschr       Date:  2011-05-23

Review 6.  Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?

Authors:  David S H Bell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Design of non-standard insulin analogs for the treatment of diabetes mellitus.

Authors:  V Pandyarajan; M A Weiss
Journal:  Curr Diab Rep       Date:  2012-12       Impact factor: 4.810

Review 8.  Evolving strategies for insulin delivery and therapy.

Authors:  William T Cefalu
Journal:  Drugs       Date:  2004       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.